| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ghana | 13 | 2021 | 333 | 0.920 |
Why?
|
| Panax | 3 | 2001 | 27 | 0.490 |
Why?
|
| Women's Health | 4 | 2011 | 2084 | 0.390 |
Why?
|
| Breast Self-Examination | 1 | 2011 | 33 | 0.380 |
Why?
|
| Faculty, Medical | 3 | 2004 | 1219 | 0.370 |
Why?
|
| Breast Neoplasms | 21 | 2021 | 21056 | 0.360 |
Why?
|
| Self Concept | 2 | 2007 | 1037 | 0.360 |
Why?
|
| Attitude to Health | 3 | 2011 | 2020 | 0.350 |
Why?
|
| Health Status | 4 | 2012 | 4080 | 0.330 |
Why?
|
| Overweight | 2 | 2018 | 2444 | 0.310 |
Why?
|
| Urban Population | 2 | 2007 | 2040 | 0.310 |
Why?
|
| Plants, Medicinal | 2 | 1999 | 166 | 0.290 |
Why?
|
| Hypertension | 5 | 2019 | 8626 | 0.270 |
Why?
|
| Carcinoembryonic Antigen | 6 | 1990 | 337 | 0.260 |
Why?
|
| Health Status Indicators | 1 | 2011 | 966 | 0.260 |
Why?
|
| Obesity | 7 | 2018 | 13076 | 0.260 |
Why?
|
| Cultural Characteristics | 1 | 2007 | 250 | 0.260 |
Why?
|
| Body Image | 2 | 2007 | 644 | 0.250 |
Why?
|
| Career Mobility | 2 | 2004 | 259 | 0.240 |
Why?
|
| Teaching | 1 | 2011 | 1169 | 0.220 |
Why?
|
| Menarche | 1 | 2006 | 532 | 0.210 |
Why?
|
| Physician Executives | 1 | 2004 | 140 | 0.210 |
Why?
|
| BCG Vaccine | 2 | 1996 | 380 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 667 | 0.200 |
Why?
|
| Melanoma, Experimental | 2 | 1996 | 558 | 0.200 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2003 | 891 | 0.200 |
Why?
|
| Small-Area Analysis | 1 | 2021 | 51 | 0.190 |
Why?
|
| Hospitals, Teaching | 3 | 2021 | 1158 | 0.190 |
Why?
|
| Chronic Disease | 2 | 2019 | 9347 | 0.190 |
Why?
|
| Health Surveys | 5 | 2021 | 4056 | 0.180 |
Why?
|
| Censuses | 1 | 2021 | 197 | 0.170 |
Why?
|
| Cyclins | 1 | 2001 | 598 | 0.160 |
Why?
|
| Health Promotion | 1 | 2011 | 2208 | 0.160 |
Why?
|
| Mentors | 1 | 2004 | 671 | 0.150 |
Why?
|
| Clothing | 1 | 2019 | 95 | 0.150 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1999 | 142 | 0.150 |
Why?
|
| Age Distribution | 2 | 2018 | 2858 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 4058 | 0.140 |
Why?
|
| Sampling Studies | 1 | 2018 | 607 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 3236 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2006 | 1950 | 0.130 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 1744 | 0.120 |
Why?
|
| Mastectomy | 2 | 2021 | 1847 | 0.120 |
Why?
|
| Indium Radioisotopes | 3 | 1990 | 113 | 0.120 |
Why?
|
| Health Behavior | 1 | 2006 | 2650 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 3230 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 7 | 2001 | 6113 | 0.120 |
Why?
|
| Leadership | 1 | 2004 | 1392 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 10 | 1997 | 9249 | 0.110 |
Why?
|
| Tamoxifen | 4 | 2007 | 963 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2018 | 2263 | 0.110 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 7838 | 0.100 |
Why?
|
| Indium | 3 | 1986 | 46 | 0.100 |
Why?
|
| Body Mass Index | 4 | 2021 | 13039 | 0.100 |
Why?
|
| Radioimmunodetection | 1 | 1992 | 45 | 0.100 |
Why?
|
| Female | 37 | 2021 | 396112 | 0.100 |
Why?
|
| Interleukin-2 | 2 | 1996 | 1896 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 320 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1993 | 1165 | 0.100 |
Why?
|
| Radioimmunotherapy | 1 | 1992 | 93 | 0.100 |
Why?
|
| Nicaragua | 1 | 2011 | 29 | 0.100 |
Why?
|
| Cystadenocarcinoma | 1 | 1991 | 54 | 0.100 |
Why?
|
| Interferon-gamma | 3 | 1997 | 3160 | 0.090 |
Why?
|
| Colonic Neoplasms | 6 | 1990 | 2531 | 0.090 |
Why?
|
| Cell Division | 6 | 2003 | 4475 | 0.090 |
Why?
|
| Radioisotopes | 3 | 1986 | 495 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1993 | 4520 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2019 | 1456 | 0.090 |
Why?
|
| Adult | 23 | 2021 | 223044 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2007 | 1534 | 0.080 |
Why?
|
| Breast Diseases | 1 | 1993 | 436 | 0.080 |
Why?
|
| Sarcoma | 2 | 1993 | 1802 | 0.080 |
Why?
|
| Middle Aged | 21 | 2018 | 223009 | 0.080 |
Why?
|
| Estrogens | 1 | 1996 | 1529 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 1153 | 0.080 |
Why?
|
| Humans | 52 | 2021 | 765968 | 0.080 |
Why?
|
| Body Size | 1 | 2012 | 459 | 0.080 |
Why?
|
| DNA, Neoplasm | 5 | 1993 | 1742 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1990 | 104 | 0.080 |
Why?
|
| Cross-Sectional Studies | 5 | 2018 | 26318 | 0.080 |
Why?
|
| Gene Amplification | 1 | 1993 | 1091 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2021 | 8532 | 0.070 |
Why?
|
| Prevalence | 4 | 2011 | 15842 | 0.070 |
Why?
|
| Body Weight | 1 | 2018 | 4622 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 1996 | 3596 | 0.070 |
Why?
|
| Demography | 2 | 2008 | 1641 | 0.070 |
Why?
|
| Contraception Behavior | 1 | 2009 | 185 | 0.070 |
Why?
|
| Receptors, Estrogen | 2 | 1994 | 2242 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2001 | 12768 | 0.070 |
Why?
|
| Social Conformity | 1 | 2006 | 39 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 1991 | 1617 | 0.070 |
Why?
|
| Risk Factors | 8 | 2018 | 74840 | 0.060 |
Why?
|
| Reproductive Medicine | 1 | 2007 | 97 | 0.060 |
Why?
|
| Family Planning Services | 1 | 2009 | 278 | 0.060 |
Why?
|
| Adolescent | 8 | 2011 | 88835 | 0.060 |
Why?
|
| Mammography | 3 | 2011 | 2423 | 0.060 |
Why?
|
| Contraception | 1 | 2009 | 361 | 0.060 |
Why?
|
| HIV Seroprevalence | 1 | 2005 | 89 | 0.060 |
Why?
|
| Flow Cytometry | 5 | 1999 | 5881 | 0.060 |
Why?
|
| Radionuclide Imaging | 7 | 1990 | 1978 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2011 | 1247 | 0.060 |
Why?
|
| Rectal Neoplasms | 4 | 1986 | 1182 | 0.060 |
Why?
|
| Planning Techniques | 1 | 2004 | 81 | 0.060 |
Why?
|
| Logistic Models | 1 | 2018 | 13266 | 0.050 |
Why?
|
| Cancer Vaccines | 2 | 2003 | 1044 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2007 | 634 | 0.050 |
Why?
|
| Educational Status | 2 | 2009 | 2513 | 0.050 |
Why?
|
| Mass Screening | 2 | 2019 | 5446 | 0.050 |
Why?
|
| Parity | 1 | 2006 | 931 | 0.050 |
Why?
|
| Aged | 12 | 2012 | 171117 | 0.050 |
Why?
|
| Young Adult | 5 | 2019 | 59889 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 1991 | 2002 | 0.050 |
Why?
|
| Social Class | 2 | 2012 | 2007 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 4900 | 0.050 |
Why?
|
| Blotting, Southern | 2 | 1993 | 772 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3432 | 0.050 |
Why?
|
| Staff Development | 1 | 2004 | 230 | 0.050 |
Why?
|
| Organizational Objectives | 1 | 2004 | 426 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2003 | 2942 | 0.050 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2001 | 220 | 0.050 |
Why?
|
| Proteins | 1 | 1996 | 5995 | 0.050 |
Why?
|
| Physician's Role | 2 | 2004 | 927 | 0.050 |
Why?
|
| Malaria | 1 | 2011 | 1246 | 0.050 |
Why?
|
| Decision Making | 2 | 2006 | 3965 | 0.050 |
Why?
|
| Anthropometry | 1 | 2006 | 1338 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2001 | 187 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 1996 | 6493 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 1993 | 1546 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2021 | 81514 | 0.050 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 1995 | 920 | 0.040 |
Why?
|
| Professional Competence | 1 | 2004 | 429 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 372 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2004 | 541 | 0.040 |
Why?
|
| RNA, Neoplasm | 2 | 1993 | 745 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2004 | 549 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2007 | 1187 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 652 | 0.040 |
Why?
|
| Counseling | 2 | 2004 | 1551 | 0.040 |
Why?
|
| Systole | 1 | 2021 | 935 | 0.040 |
Why?
|
| Adenocarcinoma | 3 | 1992 | 6364 | 0.040 |
Why?
|
| Diastole | 1 | 2021 | 785 | 0.040 |
Why?
|
| Occupational Health Services | 2 | 2019 | 150 | 0.040 |
Why?
|
| Developing Countries | 1 | 2011 | 2911 | 0.040 |
Why?
|
| Behavior | 1 | 2021 | 535 | 0.040 |
Why?
|
| HIV Infections | 1 | 2005 | 17533 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2006 | 6322 | 0.040 |
Why?
|
| BRCA1 Protein | 2 | 2003 | 1153 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 830 | 0.040 |
Why?
|
| Triglycerides | 1 | 2006 | 2441 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2019 | 6424 | 0.040 |
Why?
|
| Menopause | 1 | 2006 | 1659 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2001 | 496 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 1990 | 1377 | 0.040 |
Why?
|
| Picibanil | 1 | 1997 | 10 | 0.040 |
Why?
|
| Mobile Health Units | 1 | 2019 | 91 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2001 | 1524 | 0.040 |
Why?
|
| Memory | 1 | 2007 | 2190 | 0.040 |
Why?
|
| Mycobacterium bovis | 2 | 1997 | 148 | 0.040 |
Why?
|
| Cholesterol | 1 | 2006 | 2898 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2004 | 876 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 1998 | 9373 | 0.030 |
Why?
|
| Melanoma | 3 | 2003 | 5719 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 2033 | 0.030 |
Why?
|
| Bangladesh | 1 | 2019 | 745 | 0.030 |
Why?
|
| Age Factors | 3 | 2009 | 18380 | 0.030 |
Why?
|
| Esthetics | 1 | 1998 | 326 | 0.030 |
Why?
|
| Pain | 1 | 2011 | 5077 | 0.030 |
Why?
|
| Linear Models | 1 | 2006 | 5876 | 0.030 |
Why?
|
| Breast | 2 | 1996 | 1946 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2004 | 1406 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1999 | 616 | 0.030 |
Why?
|
| Liver Neoplasms | 3 | 1990 | 4353 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1999 | 1749 | 0.030 |
Why?
|
| RNA | 2 | 1996 | 2717 | 0.030 |
Why?
|
| RNA Helicases | 1 | 1996 | 144 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 3475 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 1997 | 579 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2006 | 9649 | 0.030 |
Why?
|
| Jews | 1 | 1996 | 357 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2009 | 59489 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 2780 | 0.030 |
Why?
|
| Cadherins | 1 | 1998 | 900 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 2354 | 0.030 |
Why?
|
| Medical Records | 1 | 2019 | 1409 | 0.030 |
Why?
|
| Mice | 8 | 2003 | 81819 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2004 | 2660 | 0.030 |
Why?
|
| Binding Sites | 1 | 2001 | 6001 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12056 | 0.030 |
Why?
|
| Fasting | 1 | 2019 | 1606 | 0.030 |
Why?
|
| Receptor, erbB-2 | 2 | 1993 | 2593 | 0.020 |
Why?
|
| Neoplasm Metastasis | 3 | 2003 | 4893 | 0.020 |
Why?
|
| Education, Medical | 1 | 2004 | 1746 | 0.020 |
Why?
|
| Paclitaxel | 1 | 1999 | 1728 | 0.020 |
Why?
|
| Th1 Cells | 1 | 1997 | 1039 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 1997 | 995 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1992 | 177 | 0.020 |
Why?
|
| Comorbidity | 1 | 2006 | 10563 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2011 | 6853 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1999 | 2920 | 0.020 |
Why?
|
| Keratins | 1 | 1993 | 498 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 1061 | 0.020 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1993 | 249 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 1998 | 1083 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1991 | 139 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 520 | 0.020 |
Why?
|
| Massachusetts | 1 | 2004 | 8875 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1998 | 2599 | 0.020 |
Why?
|
| Fibrocystic Breast Disease | 1 | 1991 | 101 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 1997 | 22332 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 1990 | 6942 | 0.020 |
Why?
|
| Mastectomy, Radical | 1 | 1990 | 19 | 0.020 |
Why?
|
| Citrates | 1 | 1990 | 130 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.020 |
Why?
|
| Citric Acid | 1 | 1990 | 124 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2019 | 1393 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1998 | 3602 | 0.020 |
Why?
|
| Genetic Engineering | 3 | 2003 | 933 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 3925 | 0.020 |
Why?
|
| Quality of Life | 1 | 2011 | 13462 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1990 | 413 | 0.020 |
Why?
|
| Estradiol | 1 | 1996 | 1947 | 0.020 |
Why?
|
| Anemia | 1 | 2019 | 1511 | 0.020 |
Why?
|
| Axilla | 1 | 1991 | 615 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1996 | 1611 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2476 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1998 | 2887 | 0.020 |
Why?
|
| Animals | 9 | 2003 | 168764 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 2844 | 0.020 |
Why?
|
| Mammaplasty | 1 | 1998 | 1264 | 0.020 |
Why?
|
| DNA | 2 | 1993 | 7202 | 0.020 |
Why?
|
| Thyroid Neoplasms | 2 | 1992 | 2371 | 0.020 |
Why?
|
| Transfection | 1 | 1995 | 5743 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 10729 | 0.020 |
Why?
|
| Contraceptive Agents | 1 | 2009 | 147 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 7425 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 12240 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 1996 | 1884 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1994 | 1050 | 0.020 |
Why?
|
| Male | 7 | 2019 | 363698 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1996 | 2796 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 1990 | 2014 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 2120 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2007 | 24282 | 0.020 |
Why?
|
| Religion | 1 | 2009 | 376 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1992 | 1180 | 0.020 |
Why?
|
| Ploidies | 3 | 1992 | 287 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 1990 | 788 | 0.020 |
Why?
|
| Cytokines | 2 | 1998 | 7421 | 0.010 |
Why?
|
| Prognosis | 6 | 1995 | 29922 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1990 | 1628 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 40065 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 3426 | 0.010 |
Why?
|
| Pregnancy | 1 | 2006 | 30260 | 0.010 |
Why?
|
| Neoplasm Staging | 3 | 1998 | 11206 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1994 | 6832 | 0.010 |
Why?
|
| Gene Expression | 2 | 1996 | 7584 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1988 | 13451 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 1990 | 703 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 41649 | 0.010 |
Why?
|
| Testis | 1 | 1986 | 780 | 0.010 |
Why?
|
| Neoplasms | 1 | 1992 | 22340 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2007 | 54802 | 0.010 |
Why?
|
| Spermatozoa | 1 | 1986 | 629 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1988 | 1229 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2004 | 327 | 0.010 |
Why?
|
| Recurrence | 1 | 1994 | 8501 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1990 | 2002 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1990 | 2394 | 0.010 |
Why?
|
| Adenoma | 1 | 1992 | 2152 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1996 | 5783 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2004 | 777 | 0.010 |
Why?
|
| Self Report | 1 | 2012 | 3770 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1996 | 8611 | 0.010 |
Why?
|
| Reoperation | 1 | 1990 | 4294 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1990 | 6309 | 0.010 |
Why?
|
| Spleen | 2 | 1997 | 2296 | 0.010 |
Why?
|
| Radiography | 1 | 1990 | 6919 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1092 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 1986 | 3454 | 0.010 |
Why?
|
| Learning | 1 | 2007 | 1755 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 1998 | 39193 | 0.010 |
Why?
|
| Nipples | 1 | 1998 | 222 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3807 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1996 | 12131 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1998 | 576 | 0.010 |
Why?
|
| Risk | 1 | 2007 | 9591 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 3797 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 2334 | 0.010 |
Why?
|
| Breast Implants | 1 | 1998 | 411 | 0.010 |
Why?
|
| Boston | 1 | 2007 | 9338 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1997 | 13648 | 0.010 |
Why?
|
| RNA, Double-Stranded | 1 | 1996 | 292 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 12403 | 0.010 |
Why?
|
| Eosinophils | 1 | 1998 | 945 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 1157 | 0.010 |
Why?
|
| Tissue Distribution | 2 | 1988 | 2266 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 5747 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1984 | 2590 | 0.010 |
Why?
|
| DNA Damage | 1 | 2003 | 2457 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1994 | 914 | 0.010 |
Why?
|
| Macrophages | 2 | 1998 | 5772 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1998 | 1098 | 0.010 |
Why?
|
| DEAD-box RNA Helicases | 1 | 1996 | 384 | 0.010 |
Why?
|
| Disease Progression | 2 | 2003 | 13632 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1998 | 779 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1998 | 1106 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1144 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 17594 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 1998 | 708 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1998 | 3618 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 8529 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3278 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1990 | 18293 | 0.010 |
Why?
|
| Public Health | 1 | 1984 | 2680 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1990 | 222 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1997 | 2352 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 1857 | 0.010 |
Why?
|
| Family Health | 1 | 1995 | 1253 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1995 | 964 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 4671 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1996 | 2601 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 1998 | 1677 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 15543 | 0.000 |
Why?
|
| Precancerous Conditions | 1 | 1996 | 976 | 0.000 |
Why?
|
| Age of Onset | 1 | 1996 | 3344 | 0.000 |
Why?
|
| Preoperative Care | 2 | 1987 | 2267 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1996 | 4108 | 0.000 |
Why?
|
| Dendritic Cells | 1 | 1998 | 2747 | 0.000 |
Why?
|
| Apoptosis | 1 | 2003 | 9514 | 0.000 |
Why?
|
| Carcinoma | 1 | 1998 | 2312 | 0.000 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1990 | 540 | 0.000 |
Why?
|
| Biopsy | 1 | 1998 | 6763 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1994 | 6220 | 0.000 |
Why?
|
| Phenotype | 1 | 2003 | 16721 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1988 | 20659 | 0.000 |
Why?
|
| Patient Selection | 1 | 1997 | 4255 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 1724 | 0.000 |
Why?
|
| Phospholipids | 1 | 1988 | 776 | 0.000 |
Why?
|
| Romania | 1 | 1984 | 97 | 0.000 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 4958 | 0.000 |
Why?
|
| Treatment Outcome | 2 | 2003 | 65188 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 18071 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 11022 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1997 | 18973 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 10261 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1997 | 4752 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 5849 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1990 | 10070 | 0.000 |
Why?
|
| Survival Rate | 1 | 1990 | 12795 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1990 | 12509 | 0.000 |
Why?
|
| Models, Theoretical | 1 | 1988 | 3564 | 0.000 |
Why?
|
| Feeding Behavior | 1 | 1984 | 3212 | 0.000 |
Why?
|
| Liver | 1 | 1986 | 7562 | 0.000 |
Why?
|
| Stress, Psychological | 1 | 1984 | 4533 | 0.000 |
Why?
|
| Child | 1 | 1990 | 80564 | 0.000 |
Why?
|